Organs-On-Chips Market is expected to foresee significant growth. North America to lead the growth!
- Vikas Kumar
- April 1, 2022
- HEALTHCARE, NEWS
- Organs-On-Chips Market Growth, Organs-On-Chips Market news, Organs-On-Chips Market share, Organs-On-Chips Market Size, Organs-On-Chips Market Trend
- 0 Comments
Organs-On-Chips Market is expected to grow at a CAGR of around 32% during the forecast period 2021-2027. The market stood at around US$ XX billion in 2020. The goal of developing organ-on-a-chip technology is to create human tissue models for disease modelling and further drug testing. Microfluidics and cells are used to mimic various physiological and mechanical conditions found in the human body. The surge in applications of organ-on-chip devices in the healthcare sector and burgeoning demand for organ-on-chip in drug screening & lung- and kidney-based organ culture are the major factors influencing global organ-on-chip market growth.
For a detailed analysis of the market drivers browse through https://univdatos.com/report/organs-on-chips-market/
Overall Organs-On-Chips industry is expected to witness strong and long-term demand, primarily due to the increase in consumption of Organs-On-Chips products coupled with rapid population growth, especially in developing countries like the India, China, Bangladesh, among others. In addition, due to lockdown imposed in the wake of COVID-19 pandemic, many manufacturing units were shutdown number of workforce declined. This further negatively impacted the growth of Global Organs-On-Chips Market.
For a detailed analysis of the Covid-19 Impact on the market browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=18572
Based on organ type, the market is bifurcated into Heart, Liver, Lung and Others. Among these segments, lung segment dominates the organs-on-chips market. The lung-on-chip technology is a three-dimensional, complex model of a living, breathing human lung on a microchip. This device, which is composed of human lung and blood vessel cells, can predict the absorption of airborne nanoparticles and mimic the inflammatory response elicited by microbial pathogens. The device can also be used to test the effects of environmental toxins, aerosolized therapeutic absorption, and the safety and efficacy of new drugs. It is expected to be used instead of animal testing. The development of new treatments for pulmonary diseases is currently of primary importance, as pulmonary diseases are among the world’s most dreadful conditions. According to World Health Organization, 10 million people fall ill with tuberculosis (TB) every year. Despite being a preventable and curable disease, 1.5 million people die from TB each year, making it the world’s top infectious killer.
Based on the application, the market is segmented into drug discovery, toxicology research, physiological model development, and others. Among these segments, the cost-effectiveness, miniaturized scale, and precise control of an organ on a chip over the mechanical and chemical microenvironment are gaining traction among pharmaceutical and biotechnology companies in order to reduce drug failure rates. The use of organs-on-chip creates a microenvironment that imitates the pathophysiological conditions of the human body, resulting in significant financial savings by replacing the trial and error method with a more reliable and efficient process. Although the number of drugs approved by the FDA has augmented from an average of 23 per year between 2000 and 2010 to 38 per year between 2011 and 2018, the average revenue per drug has reduced significantly. The latter trend is projected to continue. The decreasing average peak sales and strong competition limit the opportunity to maximize returns from new launches. Hence, the need for organ-on-chip devices is increasing for assisting in drug discovery process.
Request for Sample of the report browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=18572
For a better understanding of the market, the report is analyzed based on different regions including North America (US, Canada, Rest of North America); Europe (Germany, UK, France, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Australia, Indonesia, Bangladesh Rest of Asia-Pacific); and Rest of World. North America dominates the organ-on-chip market, owing to the rising availability of a several services offered by major players including customized designing of new chips with particular organ arrangements and surge in toxicological testing of chemicals on the different types of organ cells. In addition to this, mounting investments done by the public and private institutes for improving their research & development activities contributes to the overall market growth.
Organs-On-Chips Market Segmentation
Market Insight, by Organ Type
- Heart
- Liver
- Lung
- Others
Market Insight, by Application
- Drug Discovery
- Toxicology Research
- Physiological Model Development
- Others
Market Insight, by End-User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
Market Insight, by Region
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- UK
- France
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of World
Top Company Profiles
- MIMETAS BV
- SynVivo Inc.
- Emulate Inc.
- InSphero AG
- CN Bio
- Nortis Inc.
- Organovo Holdings Inc.
- TissUse GmbH
- AxoSim Inc.
- Kirkstall Ltd
